Patienter bør orienteres om, at behandling med lamivudin ikke har vist sig at forebygge risikoen for overførsel af hepatitis B- virus til andre, og der bør derfor fortsat tages passende forholdsregler.
Patients should be advised that therapy with lamivudine has not been proven to reduce the risk of transmission of hepatitis B virus to others and therefore, appropriate precautions should still be taken.